Tamoxifen
Tamoxifen is a SERM that antagonizes estrogen receptors in breast tissue without lowering circulating estradiol (unlike aromatase inhibitors). Pack: 100 tablets × 20 mg; label 10–20 mg/day; half-life 5–7 days. Customer reference: 10–20 mg/day prophylaxis, up to 40 mg/day for active gynecomastia-model symptoms, and ~20 mg/day for 4–6 weeks in PCT-style HPTA discussions. If estrogenic bloating persists, an AI is the complementary tool — tamoxifen does not reduce serum estradiol. Presented for laboratory research documentation only. Not for human consumption.
Identity, strength, and pack size on this listing follow the supplied product photography. Batch-specific laboratory documentation can be requested through the contact form. For laboratory research documentation only. Not for human consumption, diagnostic, or therapeutic use.
Tamoxifen is a SERM that antagonizes estrogen receptors in breast tissue without lowering circulating estradiol (unlike aromatase inhibitors). Pack: 100 tablets × 20 mg; label 10–20 mg/day; half-life 5–7 days. Customer reference: 10–20 mg/day prophylaxis, up to 40 mg/day for active gynecomastia-model symptoms, and ~20 mg/day for 4–6 weeks in PCT-style HPTA discussions. If estrogenic bloating persists, an AI is the complementary tool — tamoxifen does not reduce serum estradiol. Presented for laboratory research documentation only. Not for human consumption.
Store at 20–25°C (room temperature). Protect from direct sunlight and freezing. Restricted laboratory access — keep out of reach of children and unauthorized users.
innov8pharma presents this material for laboratory documentation. Certificate of Analysis files can be requested per batch. Not for human consumption.
| Compound | Tamoxifen citrate (Nolvadex) |
|---|---|
| Form | Oral tablets |
| Pack | 100 tablets × 20mg |
| Label dosage range | 10–20 mg/day |
| Water Retention | No |
| Aromatization | No |
| Half Life | 5–7 days |
| HBR | No |
| Acne | Rarely |
| Hepatotoxicity | Low |
| Storage | 20–25°C |